Gabelli Funds LLC Raises Holdings in Cytokinetics, Incorporated $CYTK

Gabelli Funds LLC boosted its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 313.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,759 shares of the biopharmaceutical company’s stock after purchasing an additional 26,349 shares during the quarter. Gabelli Funds LLC’s holdings in Cytokinetics were worth $1,910,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CYTK. Norges Bank acquired a new position in shares of Cytokinetics during the 2nd quarter valued at about $39,122,000. Frazier Life Sciences Management L.P. acquired a new stake in Cytokinetics during the second quarter worth about $18,328,000. Rosalind Advisors Inc. acquired a new stake in Cytokinetics during the second quarter worth about $13,216,000. Vestal Point Capital LP raised its stake in Cytokinetics by 14.8% during the second quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock worth $98,294,000 after purchasing an additional 384,469 shares during the period. Finally, AQR Capital Management LLC raised its stake in Cytokinetics by 1,639.2% during the second quarter. AQR Capital Management LLC now owns 347,739 shares of the biopharmaceutical company’s stock worth $11,489,000 after purchasing an additional 327,745 shares during the period.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Earnings call frames a “high‑stakes” commercial launch for Cytokinetics’ new heart drug — the company is shifting from development to commercialization, which can materially expand revenue if uptake meets expectations. This launch-phase narrative is the primary driver of bullish sentiment. Cytokinetics Earnings Call Marks High-Stakes Launch Phase
• Positive Sentiment: An insider exercised options worth roughly $920k+ as the heart drug hit the market — often interpreted by investors as a signal the commercial program is proceeding and that management/insiders are monetizing value created by the launch. Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
• Neutral Sentiment: Short‑interest data reported for early March shows “0” shares — this appears to be a data error or placeholder rather than meaningful short activity, so it should not be interpreted as a shift in bearish positioning.
• Negative Sentiment: Several insiders sold shares on March 9 (CEO Robert Blum sold 7,931 shares at ~$60.72; EVP Fady I. Malik sold 2,907 shares; EVP Andrew Callos sold 2,582 shares). While each insider still holds substantial positions (sales reduced holdings by low single-digit percentages), such disclosures can be read negatively by some investors as profit-taking after the launch. CEO Form 4: CEO Form 4 — EVP Malik Form 4: Malik Form 4 — EVP Callos Form 4: Callos Form 4

Insider Transactions at Cytokinetics

In other news, EVP Fady Ibraham Malik sold 2,907 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $60.72, for a total transaction of $176,513.04. Following the completion of the transaction, the executive vice president directly owned 138,629 shares in the company, valued at $8,417,552.88. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Wendell Wierenga sold 20,000 shares of Cytokinetics stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the completion of the sale, the director directly owned 32,444 shares of the company’s stock, valued at $2,145,846.16. The trade was a 38.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 96,113 shares of company stock worth $5,994,726 in the last ninety days. 3.40% of the stock is owned by company insiders.

Cytokinetics Price Performance

Shares of CYTK opened at $64.20 on Wednesday. The firm has a 50-day simple moving average of $64.02 and a two-hundred day simple moving average of $60.08. The stock has a market cap of $7.91 billion, a PE ratio of -9.83 and a beta of 0.56. Cytokinetics, Incorporated has a 1-year low of $29.31 and a 1-year high of $70.98.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million for the quarter, compared to analysts’ expectations of $8.02 million. The business’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.26) EPS. As a group, sell-side analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on CYTK. Bank of America reissued a “neutral” rating on shares of Cytokinetics in a research note on Wednesday, February 25th. UBS Group lifted their price target on shares of Cytokinetics from $61.00 to $69.00 and gave the company a “neutral” rating in a research report on Friday. The Goldman Sachs Group set a $95.00 price objective on Cytokinetics and gave the company a “buy” rating in a report on Thursday, December 18th. Barclays initiated coverage on Cytokinetics in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 price objective for the company. Finally, Truist Financial raised their target price on Cytokinetics from $84.00 to $92.00 and gave the stock a “buy” rating in a research note on Tuesday, February 3rd. Seventeen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.00.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.